Altered metabolism of apolipoprotein C.III: a contributor in chronic kidney disease?-Reference-Cited by-同舟云学术

Altered metabolism of apolipoprotein C.III: a contributor in chronic kidney disease?

Published:2011-06-01 Issue:3 Volume:6 Page:247-251
ISSN:1758-4299
Container-title:Clinical Lipidology
language:en
Short-container-title:Clinical Lipidology

Author:

Mm Ooi Esther¹,Watts Gerald²,Barrett P Hugh³

Affiliation:

1. Lipid Metabolism Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA, USA

2. Metabolic Research Centre, School of Medicine & Pharmacology, Royal Perth Hospital, University of Western Australia, Perth, Australia

3. Author for correspondence: Metabolic Research Centre, School of Medicine & Pharmacology, Royal Perth Hospital, University of Western Australia, Perth, Australia,

Publisher

Informa UK Limited

Subject

Cardiology and Cardiovascular Medicine,Endocrinology, Diabetes and Metabolism

Link

https://www.tandfonline.com/doi/pdf/10.2217/clp.11.18

Reference53 articles.

1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 351, 1296–1305 (2004).

2. Busch M, Franke S, Muller A et al.: Potential cardiovascular risk factors in chronic kidney disease: AGEs, total homocysteine and metabolites, and the C?reactive protein. Kidney Int. 66, 338–347 (2004).

3. Kaysen GA: Hyperlipidemia in chronic kidney disease. Int. J. Artif. Organs 30, 987–992 (2007).

4. Samuelsson O, Attman PO, Knight-Gibson C et al.: Lipoprotein abnormalities without hyperlipidaemia in moderate renal insufficiency. Nephrol. Dial. Transplant. 9, 1580–1585 (1994).

5. Chan DT, Irish AB, Dogra GK, Watts GF: Dyslipidaemia and cardiorenal disease: mechanisms, therapeutic opportunities and clinical trials. Atherosclerosis 196, 823–834 (2008).